Coriolis Pharma
Biopharmaceutical Research and Development Services | Coriolis Pharma.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Growth Equity VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Coriolis Pharma is a specialized service provider in the pharmaceutical industry, focusing on the development and analytical testing of biologics and virus-based drug products. The company operates in the niche market of pharmaceutical formulation and stability testing, serving clients ranging from early-stage biotech startups to established pharmaceutical companies. Coriolis Pharma's business model revolves around offering high-value analytical services, including analytical ultracentrifugation (AUC) and lyophilization modeling, which are critical for the development and post-market monitoring of biologics. The company generates revenue through service contracts and long-term partnerships with its clients, providing tailored solutions to meet specific drug development needs. Coriolis Pharma's expertise in handling complex biologics and its commitment to scientific excellence make it a trusted partner in the pharmaceutical industry.
Keywords: analytical ultracentrifugation, lyophilization modeling, biologics, virus-based drugs, pharmaceutical formulation, stability testing, biotech startups, drug development, post-market monitoring, scientific excellence.
